• Image 01
  • Image 02
  • Image 03
  • Image 04
  • Image 05
  • Image 06
Need assistance? Contact Us: 1-800-255-5897

Menu

  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude+Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Cabaletta Bio, Inc. - Common Stock (NQ:CABA)

3.385 -0.225 (-6.23%)
Streaming Delayed Price Updated: 12:48 PM EDT, May 15, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Cabaletta Bio, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9 10 Next >
News headline image
Cabaletta Bio Reports First Quarter 2026 Financial Results and Provides Business Update
May 14, 2026
From Cabaletta Bio
Via GlobeNewswire
News headline image
Cabaletta Bio Presents Preconditioning-free Clinical Data and Automated Manufacturing Translational Data for Rese-cel at ASGCT 2026 Annual Meeting
May 14, 2026
From Cabaletta Bio
Via GlobeNewswire
These stocks are moving in today's session ↗
May 04, 2026
Via Chartmill
News headline image
Cabaletta Bio Announces Pricing of $150 Million Underwritten Offering
May 04, 2026
From Cabaletta Bio
Via GlobeNewswire
Why Does Cantor Fitzgerald See Over 1,000% Potential Upside For Cabaletta Bio Stock? ↗
October 31, 2025
Via Stocktwits
News headline image
Cabaletta Bio and Cellares Announce 10-Year Commercial Supply Agreement for Rese-cel
April 28, 2026
From Cabaletta Bio
Via GlobeNewswire
News headline image
Cabaletta Bio Announces Multiple Upcoming Presentations, Including Data on Rese-cel without Preconditioning and Rese-cel with Automated Manufacturing, at the ASGCT 2026 Annual Meeting
April 27, 2026
From Cabaletta Bio
Via GlobeNewswire
News headline image
Cabaletta Bio Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update
March 23, 2026
From Cabaletta Bio
Via GlobeNewswire
News headline image
Cabaletta Bio to Participate in the TD Cowen 46th Annual Health Care Conference
February 24, 2026
From Cabaletta Bio
Via GlobeNewswire
News headline image
Cabaletta Bio to Participate in the Guggenheim Emerging Outlook: Biotech Summit 2026
February 05, 2026
From Cabaletta Bio
Via GlobeNewswire
The market is filled with gapping stocks in Thursday's session. ↗
January 22, 2026
Via Chartmill
News headline image
Cabaletta Bio Announces 2026 Strategic Priorities
January 12, 2026
From Cabaletta Bio
Via GlobeNewswire
News headline image
IND Amendment Clearance Obtained for Clinical Manufacturing of Rese-Cel from Cabaletta Bio Using Cellares' Automated Platforms
January 12, 2026
From Cellares
Via Business Wire
News headline image
Cabaletta Bio Reports Third Quarter 2025 Financial Results and Provides Business Update
November 10, 2025
From Cabaletta Bio
Via GlobeNewswire
News headline image
FDA's Rigid Approach Adds Uncertainty To uniQure's Accelerated Pathway For Huntington's Gene Therapy ↗
November 04, 2025
William Blair notes FDA's tougher stance on gene therapy programs as AMT-130 faces uncertainty in its accelerated approval timeline. 
Via Benzinga
News headline image
Cabaletta Bio to Participate in Upcoming Investor Conferences in November and December
November 04, 2025
From Cabaletta Bio
Via GlobeNewswire
News headline image
Which stocks are experiencing notable movement on Friday? ↗
October 31, 2025
Intrigued by the market activity one hour before the close of the markets on Friday? Uncover the key winners and losers of today's session in our insightful analysis. 
Via Chartmill
News headline image
Let's have a look at the top gainers and losers in the middle of the day of today's session. ↗
October 31, 2025
Curious to know what's happening on the US markets in the middle of the day on Friday? Join us as we explore the top gainers and losers in today's session. 
Via Chartmill
News headline image
12 Health Care Stocks Moving In Friday's Intraday Session ↗
October 31, 2025
 
Via Benzinga
News headline image
Let's uncover which stocks are experiencing notable gaps during today's session. ↗
October 31, 2025
Let's have a look at the gap up and gap down stocks in today's session. 
Via Chartmill
News headline image
Cabaletta Bio Presents Positive Clinical Data and Development Updates for Rese-cel at ACR Convergence 2025
October 27, 2025
From Cabaletta Bio
Via GlobeNewswire
News headline image
Cabaletta Bio Announces Appointment of Steve Gavel as Chief Commercial Officer and Award of Inducement Grant
October 14, 2025
From Cabaletta Bio
Via GlobeNewswire
News headline image
Which stocks are moving after the closing bell on Friday? ↗
October 10, 2025
Discover the top movers in Friday's after-hours session and stay informed about the post-market dynamics. 
Via Chartmill
News headline image
These stocks are moving in today's session ↗
October 09, 2025
Keep an eye on the top gainers and losers in Thursday's session, as they reflect the most notable price movements. 
Via Chartmill
News headline image
Cabaletta Bio Presents First Rese-cel Data with No Preconditioning Demonstrating Biologic Activity and Early Clinical Responses at the 2025 ESGCT Annual Congress
October 09, 2025
From Cabaletta Bio
Via GlobeNewswire
News headline image
Cabaletta Bio to Participate in Upcoming Investor Conferences in September
August 27, 2025
From Cabaletta Bio
Via GlobeNewswire
News headline image
Vinay Prasad's Comeback To FDA Sparks Debate Over Regulatory Direction ↗
August 11, 2025
Vinay Prasad returns as FDA's CBER director after brief exit, raising questions on rare disease drug approvals and mRNA vaccine oversight. 
Via Benzinga
News headline image
Cabaletta Bio (CABA) Q2 Loss Widens 30% ↗
August 07, 2025
Via The Motley Fool
Topics Intellectual Property
News headline image
Cabaletta Bio Reports Second Quarter 2025 Financial Results and Provides Business Update
August 07, 2025
From Cabaletta Bio
Via GlobeNewswire
News headline image
What's Going On With Sarepta, Capricor And Other Gene Therapy Stocks On Wednesday? ↗
July 30, 2025
Vinay Prasad exits FDA's biologics division following pressure over Sarepta's Elevidys approval and regulatory controversies. 
Via Benzinga
< Previous 1 2 3 4 5 6 7 8 9 10 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Having difficulty making your payments? We're here to help! Call 1-800-255-5897

Copyright © 2019 Franklin Credit Management Corporation
All Rights Reserved
Contact Us | Privacy Policy | Terms of Use | Sitemap